Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting

被引：8
|
作者：
Hou, Jiangxue [1 ,2 ]
Li, Yufu [1 ,2 ]
Lin, Quande [1 ,2 ]
机构：
[1] Zhengzhou Univ, Affiliated Canc Hosp, Zhengzhou 450008, Peoples R China
[2] Henan Canc Hosp, Zhengzhou 450008, Peoples R China
来源：
EXPERIMENTAL HEMATOLOGY & ONCOLOGY | 2023年 / 12卷 / 01期
关键词：
Multiple myeloma; Bispecific antibody; CAR T; Clinical trial;
D O I：
10.1186/s40164-023-00436-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Bispecific antibodies (BsAbs) and dual-targeted chimeric antigen receptor T (CAR T) cells have been employed in relapsed/refractory multiple myeloma (RRMM) patients over the past few years, as an increasing number of patients were ineffectively treated by >= 3 prior lines of therapy. BCMA/CD3 and GPRC5D/CD3 are the most popular combinations. Clinical findings indicated that patients exhibit a greater susceptibility to stronger and more enduring responses. Here, we summarize the latest data from the 2023 ASCO annual meeting on BsAbs targeting BCMA/CD3, GPRC5D/CD3 and BCMA/CD19 CAR T cells.
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting
    Jiangxue Hou
    Yufu Li
    Quande Lin
    Experimental Hematology & Oncology, 12
  • [2] BCMA-targeted CAR-T cell therapies in relapsed and/or refractory multiple myeloma: latest updates from 2023 ASCO Annual Meeting
    Wu, James F.
    Dhakal, Binod
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2023, 16 (01)
  • [3] BCMA-targeted CAR-T cell therapies in relapsed and/or refractory multiple myeloma: latest updates from 2023 ASCO Annual Meeting
    James F. Wu
    Binod Dhakal
    Journal of Hematology & Oncology, 16
  • [4] Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting
    Zhao, Juanjuan
    Ren, Quan
    Liu, Xinyuan
    Guo, Xiangqian
    Song, Yongping
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2023, 16 (01)
  • [5] Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting
    Juanjuan Zhao
    Quan Ren
    Xinyuan Liu
    Xiangqian Guo
    Yongping Song
    Journal of Hematology & Oncology, 16
  • [6] Mechanisms of resistance to CAR-T cell therapy in multiple myeloma: latest updates from the 2024 ASH annual meeting
    Hu, Yuhan
    Hou, Jiangxue
    Jiang, Zhongxing
    Lin, Quande
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2025, 14 (01)
  • [7] Dual-targeting CAR-T cells in neuroblastoma
    Sarah Crunkhorn
    Nature Reviews Drug Discovery, 2021, 20 (11) : 816 - 816
  • [8] CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting
    Xinyuan Liu
    Juanjuan Zhao
    Xiangqian Guo
    Yongping Song
    Journal of Hematology & Oncology, 16
  • [9] Bispecific antibody treatment of multiple myeloma: latest updates from the 2022 ASH annual meeting
    Yin, Xuejiao
    Liu, Yi
    Sun, Jianai
    Tong, Hongyan
    Meng, Haitao
    You, Liangshun
    THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2023, 14
  • [10] CD20 x CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting
    Liu, Xinyuan
    Zhao, Juanjuan
    Guo, Xiangqian
    Song, Yongping
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2023, 16 (01)
12345